SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.
2018 Cantor Global Healthcare Conference
Management will present a corporate overview at the 2018 Cantor Global Healthcare Conference, which is being held in New York on October 1-3, 2018.
Details of the presentation are as follows:
Monday, October 1 at 1:45 - 2:15 PM ET (webcast available)
Intercontinental Barclay Hotel, New York
Empire Ballroom 1
The company will also participate in 1-on-1 meetings at the Cantor conference.
2018 BIO Investor Forum
The company will attend and participate in 1-on-1 meetings at the 2018 BIO Investor Forum. The conference is being held in San Francisco on October 17-18, 2018, at the Westin St. Francis.
BTIG Biotechnology Conference
The company will attend and participate in the BTIG Biotechnology Conference, which is being held in New York on October 25, 2018, at the Langham Hotel.
To access the live webcast of the Cantor presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a small molecule thyroid beta agonist. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content. VK2809 was shown to be safe and well-tolerated in the study. The company's second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared to patients who received placebo. The company is also developing VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Additional programs include novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia. Viking holds exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
SOURCE Viking Therapeutics, Inc.